Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3239-3253

  Maloney, Alison ^a   Clarke, Paul A ^a   Naaby Hansen, Soren ^c   Stein, Rob ^c,d   Koopman, Jens Oliver ^c   Akpan, Akunna ^c   Yang, Alice ^c   Zvelebil, Marketa ^c   Cramer, Rainer ^c   Stimson, Lindsay ^a   Aherne, Wynne ^a   Banerji, Udai ^a,b   Judson, Ian ^a,b   Sharp, Swee ^a   Powers, Marissa ^a   DeBilly, Emmanuel ^a   Salmons, Joanne ^a   Walton, Michael ^a   Burlingame, Al ^c   Waterfield, Michael ^c   Workman, Paul ^a,e   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; CCT 018159; CCT 066961; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 47; HEAT SHOCK PROTEIN 72; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HETEROCHROMATIN PROTEIN 1; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE 1; HISTONE ARGININE METHYL TRANSFERASE PRMT5; MESSENGER RNA; METHYLTRANSFERASE; MYC PROTEIN; NSC 683201; RADICICOL; TRICHOSTATIN A; UNCLASSIFIED DRUG; VER 49009; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM; MACROLIDE; PRMT5 PROTEIN, HUMAN; PROTEIN METHYLTRANSFERASE; TUMOR PROTEIN;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CASE REPORT; CHROMATIN; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MESOTHELIOMA; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TUMOR BIOPSY; UNINDEXED SEQUENCE; WESTERN BLOTTING; BIOPSY; BIOSYNTHESIS; CELL STRAIN HCT116; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ACETYLATION; BENZOQUINONES; BIOPSY; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HCT116 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MACROLIDES; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEIN METHYLTRANSFERASES; PROTEOMICS;

EID: 34147150867     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2968     Document Type: Article

References (59)

1. Clarke PA, te Poele R, Workman P. Gene expression microarray technologies in the development of new therapeutic agents. Eur J Cancer 2004;40:2560-91.
2. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 2002;1: 683-95.
3. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006;31:164-72.
4. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
5. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006;95:323-48.
6. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004;206:149-57.
7. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91: 1940-9.
8. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 2002;8:986-93.
9. Burger AM, Fiebig HH, Stinson SF, Sausville EA. 17-(Allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 2004;15: 377-87.
10. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23: 4152-61.
11. Pacey S, Banerji U, Judson I, Workman P. Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 2006;12:331-58.
12. Clarke PA, Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000;19:4125-33.
13. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul 1984;22: 27-55.
14. Page MJ, Amess B, Townsend RR, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci U S A 1999;96:12589-94.
15. Harris RA, Yang A, Stein RC, et al. Cluster analysis of an extensive human breast cancer cell line protein expression map database. Proteomics 2002;2:212-23.
16. Clauser KR, Hall SC, Smith DM, et al. Rapid mass spectrometric peptide sequencing and mass matching for characterization of human melanoma proteins isolated by two-dimensional PAGE. Proc Natl Acad Sci U S A 1995;92:5072-6.
17. Naaby-Hansen S, Nagano K, Gaffney P, Masters JR, Cramer R. Proteomics in the analysis of prostate cancer. Methods Mol Med 2003;81:277-97.
18. Benvenuti S, Cramer R, Quinn CC, et al. Differential proteome analysis of replicative senescence in rat embryo fibroblasts. Mol. Cell Proteomics 2002;1:280-92.
19. Clark J, Edwards S, John M, et al. Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer 2002;34:104-14.
20. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
21. Clarke PA, George ML, Easdale S, et al. Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer Res 2003;63: 6855-63.
22. Coller HA, Grandori C, Tamayo P, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 2000; 97:3260-5.
23. Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 2002;10:1307-18.
24. Honore B, Vorum H, Baandrup U. hnRNPs H, H′ and F behave differently with respect to posttranslational cleavage and subcellular localization. FEBS Lett 1999; 456:274-80.
25. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 2004; 96:990-7.
26. McCollum AK, Teneyck CJ, Sauer BM, Toft DO, Erlichman C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res 2006;66:10967-75.
27. Cheung KM, Matthews TP, James K, et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005;15:3338-43.
28. Dymock BW, Barril X, Brough PA, et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 2005;48:4212-5.
29. Maloney A, Clarke PA, Workman P. Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr Cancer Drug Targets 2003;3:331-41.
30. Finishing the euchromatic sequence of the human genome. Nature 2004;431:931-45.
31. Wilkins MR, Gasteiger E, Sanchez JC, Bairoch A, Hochstrasser DF. Two-dimensional gel electrophoresis for proteome projects: the effects of protein hydrophobicity and copy number. Electrophoresis 1998;19: 1501-5.
32. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998;94:471-80.
33. Stephanou A, Latchman DS. Transcriptional regulation of the heat shock protein genes by STAT family transcription factors. Gene Expr 1999;7:311-9.
34. Han SI, Oh SY, Woo SH, et al. Implication of a small GTPase Rac1 in the activation of c-Jun N-terminal kinase and heat shock factor in response to heat shock. J Biol Chem 2001;276:1889-95.
35. Wadhwa R, Taira K, Kaul SC. An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where? Cell Stress Chaperones 2002;7:309-16.
36. Mehlen P, Schulze-Osthoff K, Arrigo AP. Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death. J Biol Chem 1996;271:16510-4.
37. Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000;2:469-75.
38. Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 2000;19:4310-22.
39. Tasab M, Batten MR, Bulleid NJ. Hsp47: a molecular chaperone that interacts with and stabilizes correctly-folded procollagen. EMBO J 2000;19:2204-11.
40. Sasaki H, Sato T, Yamauchi N, et al. Induction of heat shock protein 47 synthesis by TGF-beta and IL-1 beta via enhancement of the heat shock element binding activity of heat shock transcription factor 1. J Immunol 2002;168:5178-83.
41. Yang Q, Liu S, Tian Y, et al. Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma Cancer Res 2004;64:4531-8.
42. Chen Y, Schnetz MP, Irarrazabal CE, et al. Proteomic identification of proteins associated with the osmoregulatory transcription factor TonEBP/OREBP; functional effects of Hsp90 and PARP-1. Am J Physiol Renal Physiol 2006. Epub ahead of print 2006 Dec 5.
43. Teng SC, Chen YY, Su YN, et al. Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformation. J Biol Chem 2004;279: 14649-55.
44. Stepanova L, Finegold M, DeMayo F, Schmidt EV, Harper JW. The oncoprotein kinase chaperone CDC37 functions as an oncogene in mice and collaborates with both c-myc and cyclin D1 in transformation of multiple tissues. Mol Cell Biol 2000;20:4462-73.
45. Kamakaka RT. Heterochromatin: proteins in flux lead to stable repression. Curr Biol 2003;13:R317-9.
46. Verreault A, Kaufman PD, Kobayashi R, Stillman B. Nucleosomal DNA regulates the core-histone-binding subunit of the human Hat1 acetyltransferase. Curr Biol 1998;8:96-108.
47. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94: 504-13.
48. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-34.
49. Sangster TA, Queitsch C, Lindquist S. Hsp90 and chromatin: where is the link? Cell Cycle 2003;2:166-8.
50. Zhao R, Davey M, Hsu YC, et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005;120:715-27.
51. Huang HC, Liu YC, Liu SH, Tzang BS, Lee WC. Geldanamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells. Life Sci 2002;70:1763-75.
52. Rahmani M, Yu C, Dai Y, et al. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. Cancer Res 2003;63: 8420-7.
53. Pal S, Vishwanath SN, Erdjument-Bromage H, Tempst P, Sif S, Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol 2004;24:9630-45.
54. Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004;6:731-40.
55. Banerji U, Walton M, Raynaud F, et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005;11: 7023-32.
56. Zhang H, Chung D, Yang YC, et al. Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 2006;5:1256-64.
57. Kaul SC, Yaguchi T, Taira K, Reddel RR, Wadhwa R. Overexpressed mortalin (mot-2)/mthsp70/GRP75 and hTERT cooperate to extend the in vitro lifespan of human fibroblasts. Exp Cell Res 2003;286:96-101.
58. Hong Y, Sarge KD. Regulation of protein phosphatase 2A activity by heat shock transcription factor 2. J Biol Chem 1999;274:12967-70.
59. Mahe D, Mahl P, Gattoni R, et al. Cloning of human 2H9 heterogeneous nuclear ribonucleoproteins. Relation with splicing and early heat shock-induced splicing arrest. J Biol Chem 1997;272:1827-36.